Ada Health, which offers an AI-driven symptom assessment app for patients, raises $90M Series B led by Leaps by Bayer
The digital health space continues cooking on gas: Berlin-based Ada Health has closed a $90M Series B round of funding led by Leaps by Bayer, the impact investment arm …
Context & Ripple Effects
This round doubles down on an arc that started in 2017, when Berlin-based Ada Health raised $47M led by Access Industries to build what was then pitched as an Alexa-like medical assistant. The lead here is telling: Leaps is Bayer's impact-investment arm, and it extends a pharma strategy already visible in Bayer's earlier backing of Medopad's disease-progression indicators.
The money also lands in a crowded European lane. Your.MD had raised €25M for its Healthily self-care app, Kaia Health was approaching $50M total, and Poland-based Infermedica followed within months with its own $30M Series B — so Ada's scale-up is as much about outlasting rivals as building the product.
First-order effects
- Ada Health gets roughly double its prior disclosed raise to push its symptom-assessment app into wider distribution, while Bayer secures a front-door position in patient triage on top of its Medopad stake.
Second-order effects
- Rival European symptom checkers — Your.MD's Healthily and Infermedica among them — face pressure to match Ada's war chest, pushing them toward larger rounds and deeper integration with payers or providers.
Third-order effects
- If pharma corporate venture keeps anchoring triage apps, patient-facing symptom assessment consolidates around drugmakers' ecosystems rather than standalone consumer brands — a pattern the later emergence of orchestration players like Qualified Health only sharpens.
The trend: Pharma corporate venture arms are turning AI symptom checkers into the strategic entry point of digital health, with Bayer now holding positions at both ends of the patient journey.